The profile contains critical company information including:
- Business description - A detailed description of the company’s operations and business divisions.
- Corporate strategy - Analyst’s summarization of the company’s business strategy.
- SWOT Analysis - A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives’ employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights
Aptevo Therapeutics Inc (Aptevo) is a clinical-stage biotechnology company focused on the research and development of novel immunotherapy candidates for cancer treatment. It is developing innovative immunotherapy candidates for cancer treatment using its Adaptir and Adaptir-Flex platforms that enable the creation of monospecific, bispecific, and multispecific immunotherapeutic proteins to enhance or regulate immune responses. Aptevo's major products include clinical candidates mipletamig and ALG.APV-527, as well as several preclinical candidates, including APVO603, a dual agonist that targets both 4-1BB and OX40; APVO442, which is designed for prostate cancer; and APVO711, which stimulates CD40 while inhibiting the PD-1/PD-L1 pathway. It’s products are designed for applications in oncology, targeting various forms of cancer. The company collaborates with partners such as Alligator Bioscience for the development of certain therapies. Aptevo is headquartered in Seattle, Washington, the US.Aptevo Therapeutics Inc Key Recent Developments
- Sep 04, 2025: Aptevo Unveils Two Next-Generation, Industry Leading Trispecifics, Expanding CD3 Oncology Pipeline to Five Molecules
- Aug 11, 2025: Aptevo Therapeutics Posts 2Q25 Results and Announces Business Update
- Jun 20, 2025: Aptevo Expands Differentiated CD3 Portfolio with APVO455, Advancing a Suite of Targeted T-cell Engagers
- May 15, 2025: Aptevo Therapeutics Reports 1Q25 Financial Results And Provides an Update on Mipletamig
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- MacroGenics Inc
- Genmab AS
- Regeneron Pharmaceuticals Inc
- AbbVie Inc
- Bristol-Myers Squibb Co
- Gilead Sciences Inc
- Amgen Inc

